UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) March 15, 2005
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-32177 |
|
22-2407152 |
|
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File No.) |
|
(I.R.S.
Employer
Identification
No.) |
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item
2.02. Results of Operations and Financial Condition.
On March
15, 2005, NovaDel Pharma Inc. (the “Company”) issued a press release to report
its financial results for the quarter ended January 31, 2005. A copy of the
press release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this
Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Press
release dated March 15, 2005, titled “NovaDel Reports Second Fiscal and Six
Month Result.”
This
press release is being furnished pursuant to Item 9.01 of this Current Report on
Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
NovaDel Pharma
Inc. |
|
|
|
|
By: |
/s/ Jean W. Frydman |
| |
Name: Jean
W. Frydman |
| |
Title:
Vice
President, General Counsel
and
Corporate Secretary |
Date:
March 17, 2005